Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients
We explored the utility of novel biomarkers, presepsin and interferon-λ3 (IFN-λ3), for predicting disease severity and clinical outcomes in hospitalized Coronavirus (COVID-19) patients. In a total of 55 patients (non-critical, <i>n</i> = 16; critical, <i>n</i> = 39), presepsi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/14/2372 |
| _version_ | 1827733306505953280 |
|---|---|
| author | Gun-Hyuk Lee Mikyoung Park Mina Hur Hanah Kim Seungho Lee Hee-Won Moon Yeo-Min Yun |
| author_facet | Gun-Hyuk Lee Mikyoung Park Mina Hur Hanah Kim Seungho Lee Hee-Won Moon Yeo-Min Yun |
| author_sort | Gun-Hyuk Lee |
| collection | DOAJ |
| description | We explored the utility of novel biomarkers, presepsin and interferon-λ3 (IFN-λ3), for predicting disease severity and clinical outcomes in hospitalized Coronavirus (COVID-19) patients. In a total of 55 patients (non-critical, <i>n</i> = 16; critical, <i>n</i> = 39), presepsin and IFN-λ3 were compared with sequential organ failure assessment (SOFA) scores and age. Disease severity and clinical outcomes (in-hospital mortality, intensive care unit admission, ventilator use, and kidney replacement therapy) were analyzed using receiver operating characteristic (ROC) curves. In-hospital mortality was also analyzed using the Kaplan-Meier method with hazard ratios (HR). SOFA scores, age, presepsin, and IFN-λ3 predicted disease severity comparably (area under the curve [AUC], 0.67–0.73). SOFA score and IFN-λ3 predicted clinical outcomes comparably (AUC, 0.68–0.88 and 0.66–0.74, respectively). Presepsin predicted in-hospital mortality (AUC = 0.74). The combination of presepsin and IFN-λ3 showed a higher mortality risk than SOFA score or age (HR [95% confidence interval, CI], 6.7 [1.8–24.1]; 3.6 [1.1–12.1]; 2.8 [0.8–9.6], respectively) and mortality rate further increased when presepsin and IFN-λ3 were added to SOFA scores or age (8.5 [6.8–24.6], 4.2 [0.9–20.6], respectively). In the elderly (≥65 years), in-hospital mortality rate was significantly higher when both presepsin and IFN-λ3 levels increased than when either one or no biomarker level increased (88.9% vs. 14.3%, <i>p</i> < 0.001). Presepsin and IFN-λ3 predicted disease severity and clinical outcomes in hospitalized COVID-19 patients. Both biomarkers, whether alone or added to the clinical assessment, could be useful for managing COVID-19 patients, especially the elderly. |
| first_indexed | 2024-03-11T01:09:38Z |
| format | Article |
| id | doaj.art-565fa6a227084be9bf27c875068b2e1c |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T01:09:38Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-565fa6a227084be9bf27c875068b2e1c2023-11-18T18:57:51ZengMDPI AGDiagnostics2075-44182023-07-011314237210.3390/diagnostics13142372Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 PatientsGun-Hyuk Lee0Mikyoung Park1Mina Hur2Hanah Kim3Seungho Lee4Hee-Won Moon5Yeo-Min Yun6Department of Laboratory Medicine, Konkuk University School of Medicine, Konkuk University Medical Center, 120-1, Neungdong-ro, Hwayang-dong, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Laboratory Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Republic of KoreaDepartment of Laboratory Medicine, Konkuk University School of Medicine, Konkuk University Medical Center, 120-1, Neungdong-ro, Hwayang-dong, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Laboratory Medicine, Konkuk University School of Medicine, Konkuk University Medical Center, 120-1, Neungdong-ro, Hwayang-dong, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Preventive Medicine, College of Medicine, Dong-A University, Busan 49201, Republic of KoreaDepartment of Laboratory Medicine, Konkuk University School of Medicine, Konkuk University Medical Center, 120-1, Neungdong-ro, Hwayang-dong, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Laboratory Medicine, Konkuk University School of Medicine, Konkuk University Medical Center, 120-1, Neungdong-ro, Hwayang-dong, Gwangjin-gu, Seoul 05030, Republic of KoreaWe explored the utility of novel biomarkers, presepsin and interferon-λ3 (IFN-λ3), for predicting disease severity and clinical outcomes in hospitalized Coronavirus (COVID-19) patients. In a total of 55 patients (non-critical, <i>n</i> = 16; critical, <i>n</i> = 39), presepsin and IFN-λ3 were compared with sequential organ failure assessment (SOFA) scores and age. Disease severity and clinical outcomes (in-hospital mortality, intensive care unit admission, ventilator use, and kidney replacement therapy) were analyzed using receiver operating characteristic (ROC) curves. In-hospital mortality was also analyzed using the Kaplan-Meier method with hazard ratios (HR). SOFA scores, age, presepsin, and IFN-λ3 predicted disease severity comparably (area under the curve [AUC], 0.67–0.73). SOFA score and IFN-λ3 predicted clinical outcomes comparably (AUC, 0.68–0.88 and 0.66–0.74, respectively). Presepsin predicted in-hospital mortality (AUC = 0.74). The combination of presepsin and IFN-λ3 showed a higher mortality risk than SOFA score or age (HR [95% confidence interval, CI], 6.7 [1.8–24.1]; 3.6 [1.1–12.1]; 2.8 [0.8–9.6], respectively) and mortality rate further increased when presepsin and IFN-λ3 were added to SOFA scores or age (8.5 [6.8–24.6], 4.2 [0.9–20.6], respectively). In the elderly (≥65 years), in-hospital mortality rate was significantly higher when both presepsin and IFN-λ3 levels increased than when either one or no biomarker level increased (88.9% vs. 14.3%, <i>p</i> < 0.001). Presepsin and IFN-λ3 predicted disease severity and clinical outcomes in hospitalized COVID-19 patients. Both biomarkers, whether alone or added to the clinical assessment, could be useful for managing COVID-19 patients, especially the elderly.https://www.mdpi.com/2075-4418/13/14/2372presepsininterferon-λ3COVID-19severityin-hospital mortalitySOFA score |
| spellingShingle | Gun-Hyuk Lee Mikyoung Park Mina Hur Hanah Kim Seungho Lee Hee-Won Moon Yeo-Min Yun Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients Diagnostics presepsin interferon-λ3 COVID-19 severity in-hospital mortality SOFA score |
| title | Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients |
| title_full | Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients |
| title_fullStr | Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients |
| title_full_unstemmed | Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients |
| title_short | Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients |
| title_sort | utility of presepsin and interferon λ3 for predicting disease severity and clinical outcomes in covid 19 patients |
| topic | presepsin interferon-λ3 COVID-19 severity in-hospital mortality SOFA score |
| url | https://www.mdpi.com/2075-4418/13/14/2372 |
| work_keys_str_mv | AT gunhyuklee utilityofpresepsinandinterferonl3forpredictingdiseaseseverityandclinicaloutcomesincovid19patients AT mikyoungpark utilityofpresepsinandinterferonl3forpredictingdiseaseseverityandclinicaloutcomesincovid19patients AT minahur utilityofpresepsinandinterferonl3forpredictingdiseaseseverityandclinicaloutcomesincovid19patients AT hanahkim utilityofpresepsinandinterferonl3forpredictingdiseaseseverityandclinicaloutcomesincovid19patients AT seungholee utilityofpresepsinandinterferonl3forpredictingdiseaseseverityandclinicaloutcomesincovid19patients AT heewonmoon utilityofpresepsinandinterferonl3forpredictingdiseaseseverityandclinicaloutcomesincovid19patients AT yeominyun utilityofpresepsinandinterferonl3forpredictingdiseaseseverityandclinicaloutcomesincovid19patients |